Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Identifieur interne : 000397 ( PubMed/Curation ); précédent : 000396; suivant : 000398Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Auteurs : Clive Ballard [Royaume-Uni] ; Stuart Isaacson [États-Unis] ; Roger Mills [États-Unis] ; Hilde Williams [États-Unis] ; Anne Corbett [Royaume-Uni] ; Bruce Coate [États-Unis] ; Rajesh Pahwa [États-Unis] ; Olivier Rascol [France] ; David J. Burn [Royaume-Uni]Source :
- Journal of the American Medical Directors Association [ 1538-9375 ] ; 2015.
English descriptors
- KwdEn :
- Accidental Falls (statistics & numerical data), Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Antipsychotic Agents (administration & dosage), Antipsychotic Agents (adverse effects), Drug Therapy, Combination, Edema (epidemiology), Female, Humans, Hypotension, Orthostatic (epidemiology), Infection (epidemiology), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (mortality), Piperidines (therapeutic use), Psychotic Disorders (drug therapy), Psychotic Disorders (etiology), Stroke (epidemiology), Thromboembolism (epidemiology), Urea (analogs & derivatives), Urea (therapeutic use).
- MESH :
- chemical , administration & dosage : Antipsychotic Agents.
- chemical , adverse effects : Antipsychotic Agents.
- chemical , analogs & derivatives : Urea.
- chemical , therapeutic use : Antiparkinson Agents, Piperidines, Urea.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease, Psychotic Disorders.
- epidemiology : Edema, Hypotension, Orthostatic, Infection, Stroke, Thromboembolism.
- etiology : Psychotic Disorders.
- mortality : Parkinson Disease.
- statistics & numerical data : Accidental Falls.
- Adult, Aged, Aged, 80 and over, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
To establish the mortality risk and adverse events associated with the use of atypical antipsychotic medications in people with Parkinson disease psychosis (PDP) in a clinically defined trial cohort.
DOI: 10.1016/j.jamda.2015.06.021
PubMed: 26239690
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000397
Links to Exploration step
pubmed:26239690Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.</title><author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name><affiliation wicri:level="1"><nlm:affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK. Electronic address: clive.ballard@kcl.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Centre for Age-Related Diseases, King's College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Isaacson, Stuart" sort="Isaacson, Stuart" uniqKey="Isaacson S" first="Stuart" last="Isaacson">Stuart Isaacson</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton</wicri:cityArea></affiliation></author><author><name sortKey="Mills, Roger" sort="Mills, Roger" uniqKey="Mills R" first="Roger" last="Mills">Roger Mills</name><affiliation wicri:level="2"><nlm:affiliation>ACADIA Pharmaceuticals, San Diego, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>ACADIA Pharmaceuticals, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Williams, Hilde" sort="Williams, Hilde" uniqKey="Williams H" first="Hilde" last="Williams">Hilde Williams</name><affiliation wicri:level="2"><nlm:affiliation>ACADIA Pharmaceuticals, San Diego, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>ACADIA Pharmaceuticals, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Corbett, Anne" sort="Corbett, Anne" uniqKey="Corbett A" first="Anne" last="Corbett">Anne Corbett</name><affiliation wicri:level="1"><nlm:affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Centre for Age-Related Diseases, King's College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Coate, Bruce" sort="Coate, Bruce" uniqKey="Coate B" first="Bruce" last="Coate">Bruce Coate</name><affiliation wicri:level="2"><nlm:affiliation>ACADIA Pharmaceuticals, San Diego, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>ACADIA Pharmaceuticals, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation wicri:level="2"><nlm:affiliation>University of Kansas Medical Center, Kansas City, KS.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Kansas</region></placeName><wicri:cityArea>University of Kansas Medical Center, Kansas City</wicri:cityArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Neuroscience, Newcastle University, Newcastle, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neuroscience, Newcastle University, Newcastle</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26239690</idno><idno type="pmid">26239690</idno><idno type="doi">10.1016/j.jamda.2015.06.021</idno><idno type="wicri:Area/PubMed/Corpus">000397</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000397</idno><idno type="wicri:Area/PubMed/Curation">000397</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000397</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.</title><author><name sortKey="Ballard, Clive" sort="Ballard, Clive" uniqKey="Ballard C" first="Clive" last="Ballard">Clive Ballard</name><affiliation wicri:level="1"><nlm:affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK. Electronic address: clive.ballard@kcl.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Centre for Age-Related Diseases, King's College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Isaacson, Stuart" sort="Isaacson, Stuart" uniqKey="Isaacson S" first="Stuart" last="Isaacson">Stuart Isaacson</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton</wicri:cityArea></affiliation></author><author><name sortKey="Mills, Roger" sort="Mills, Roger" uniqKey="Mills R" first="Roger" last="Mills">Roger Mills</name><affiliation wicri:level="2"><nlm:affiliation>ACADIA Pharmaceuticals, San Diego, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>ACADIA Pharmaceuticals, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Williams, Hilde" sort="Williams, Hilde" uniqKey="Williams H" first="Hilde" last="Williams">Hilde Williams</name><affiliation wicri:level="2"><nlm:affiliation>ACADIA Pharmaceuticals, San Diego, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>ACADIA Pharmaceuticals, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Corbett, Anne" sort="Corbett, Anne" uniqKey="Corbett A" first="Anne" last="Corbett">Anne Corbett</name><affiliation wicri:level="1"><nlm:affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Centre for Age-Related Diseases, King's College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Coate, Bruce" sort="Coate, Bruce" uniqKey="Coate B" first="Bruce" last="Coate">Bruce Coate</name><affiliation wicri:level="2"><nlm:affiliation>ACADIA Pharmaceuticals, San Diego, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>ACADIA Pharmaceuticals, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation wicri:level="2"><nlm:affiliation>University of Kansas Medical Center, Kansas City, KS.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Kansas</region></placeName><wicri:cityArea>University of Kansas Medical Center, Kansas City</wicri:cityArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Neuroscience, Newcastle University, Newcastle, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neuroscience, Newcastle University, Newcastle</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of the American Medical Directors Association</title><idno type="eISSN">1538-9375</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accidental Falls (statistics & numerical data)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antipsychotic Agents (administration & dosage)</term><term>Antipsychotic Agents (adverse effects)</term><term>Drug Therapy, Combination</term><term>Edema (epidemiology)</term><term>Female</term><term>Humans</term><term>Hypotension, Orthostatic (epidemiology)</term><term>Infection (epidemiology)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (mortality)</term><term>Piperidines (therapeutic use)</term><term>Psychotic Disorders (drug therapy)</term><term>Psychotic Disorders (etiology)</term><term>Stroke (epidemiology)</term><term>Thromboembolism (epidemiology)</term><term>Urea (analogs & derivatives)</term><term>Urea (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Urea</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Piperidines</term><term>Urea</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Edema</term><term>Hypotension, Orthostatic</term><term>Infection</term><term>Stroke</term><term>Thromboembolism</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Accidental Falls</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To establish the mortality risk and adverse events associated with the use of atypical antipsychotic medications in people with Parkinson disease psychosis (PDP) in a clinically defined trial cohort.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26239690</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>05</Day></DateCreated><DateCompleted><Year>2016</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-9375</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Directors Association</Title><ISOAbbreviation>J Am Med Dir Assoc</ISOAbbreviation></Journal><ArticleTitle>Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.</ArticleTitle><Pagination><MedlinePgn>898.e1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jamda.2015.06.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-8610(15)00442-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To establish the mortality risk and adverse events associated with the use of atypical antipsychotic medications in people with Parkinson disease psychosis (PDP) in a clinically defined trial cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Post hoc analysis of data from a multicenter, open-label extension study of pimavanserin comparing people taking and not taking current antipsychotics.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Primary and secondary care medical centers in the United States, Canada, Europe, and India.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 459 people with PDP enrolled in the extension study. Participants were between ages 30 and 80 years, and had an established diagnosis of idiopathic Parkinson disease and moderate to severe psychosis.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants were categorized into 2 groups: those receiving concomitant antipsychotic medications ("concurrent APD") and those who did not take antipsychotic medications at any time during the study ("no APD"). Participants were receiving 40 mg pimavanserin daily in addition to concurrent antipsychotics and Parkinson disease medications.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Safety assessments at 2 weeks; 1, 3, 6, 9, and 12 months; and every 6 months thereafter, including evaluation of adverse events (AEs), vital signs, weight, physical examinations, 12-lead electrocardiograms, clinical laboratory tests (serum chemistry, hematology, and urinalysis), and the Unified Parkinson's Disease Rating Scale Parts II and III (UPDRS-II+III, activities of daily living and motor impairment, respectively). Differences between participants taking and not taking current antipsychotics were evaluated using incidence rate ratios (IRRs) with 95% confidence intervals (CIs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was significant increase in the mortality rate for participants taking concurrent antipsychotics compared with the group not taking antipsychotic medications (IRR 4.20, 95% CI 2.13-7.96). Participants who received a concurrent antipsychotic were also significantly more likely to experience overall a serious AE (IRR 2.95, 95% CI 2.02-4.24), any antipsychotic-related event (IRR 1.66, 95% CI 1.18-2.29), cognition-related events (IRR 2.70, 95% CI 1.19-5.58), infections (IRR 1.97, 95% CI 1.17-3.16), and edema (IRR 2.61, 95% CI 1.09-5.59). The risk of falls, stroke, sedation, orthostatic hypotension, and thromboembolic events was also increased in these individuals but this was not significant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study highlights a significant risk of mortality, and severe AEs in patients with Parkinson disease receiving atypical antipsychotics. This is similar to or greater than the risks seen in people with Alzheimer disease, although with a less clear-cut risk of stroke and a longer delay to increased mortality.</AbstractText><CopyrightInformation>Copyright © 2015 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK. Electronic address: clive.ballard@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacson</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coate</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals, San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Kansas Medical Center, Kansas City, KS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Newcastle University, Newcastle, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00550238</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Med Dir Assoc</MedlineTA><NlmUniqueID>100893243</NlmUniqueID><ISSNLinking>1525-8610</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W8T17847W</RegistryNumber><NameOfSubstance UI="D014508">Urea</NameOfSubstance></Chemical><Chemical><RegistryNumber>JZ963P0DIK</RegistryNumber><NameOfSubstance UI="C510793">pimavanserin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007024" MajorTopicYN="N">Hypotension, Orthostatic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson disease</Keyword><Keyword MajorTopicYN="N">antipsychotics</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>06</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26239690</ArticleId><ArticleId IdType="pii">S1525-8610(15)00442-9</ArticleId><ArticleId IdType="doi">10.1016/j.jamda.2015.06.021</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000397 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000397 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26239690
|texte= Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26239690" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |